Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical AB's revenue per share for the
three
months ended in May. 2026 was €0.00.
Diamyd Medical AB's revenue per share for the trailing twelve months (TTM) ended in May. 2026 was €0.00.
Warning Sign:
Diamyd Medical AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Diamyd Medical AB was 200.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -45.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -29.10% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Diamyd Medical AB's Revenue per Share or its related term are showing as below:
FRA:DMN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -87.3 Med: -32.5 Max: 63
Current: -45
During the past 13 years, Diamyd Medical AB's highest 3-Year average Revenue Per Share Growth Rate was 63.00% per year. The lowest was -87.30% per year. And the median was -32.50% per year.
FRA:DMN's 3-Year Revenue Growth Rate is ranked worse than 88.77% of 766
companies
in the Biotechnology industry
Industry Median: 3.35
vs FRA:DMN: -45.00
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Diamyd Medical AB Revenue per Share Related Terms
Diamyd Medical AB Revenue per Share Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMN vs VRTX, REGN, MRNA: Revenue per Share Comparison
For the Biotechnology subindustry, Diamyd Medical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Diamyd Medical AB's Revenue Per Share for the fiscal year that ended in Aug. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (FRA:DMN) has a Revenue per Share of €0.00 as of May. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Diamyd Medical AB and its competitors. According to the industry distribution chart, Diamyd Medical AB ranks #680 out of 766 companies in the Biotechnology industry, placing it in the top 88.8%.
Is Diamyd Medical AB's Revenue per Share too high?
Diamyd Medical AB's current Revenue per Share is €0.00. Based on the distribution chart, Diamyd Medical AB ranks #680 out of 766 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #680 out of 766 companies for Revenue per Share. This places Diamyd Medical AB in the lower half of its industry. The industry median Revenue per Share is 3.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.35, based on 766 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 0.9% below its estimated fair value. The current Revenue per Share is €0.00. Diamyd Medical AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Revenue per Share is €0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of €0.07 is trading 0.9% below its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Fairly Valued.
Key valuation signals for FRA:DMN:
Revenue per Share: €0.00
GF Value™: €0.07 vs. price of €0.07 (0.9% below fair value)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB is a Swedish clinical-stage biopharmaceutical company developing precision-medicine, antigen-specific immunotherapies for type 1 diabetes. Its lead candidate, Diamyd (recombinant human GAD65 formulated with alum), is designed to preserve endogenous insulin production in patients carrying the HLA DR3-DQ2 genotype. The therapy is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in recently diagnosed type 1 diabetes and in the DiaPrecise trial in children with earlier-stage disease. The company also develops the vitamin D-based candidate Alum and conducts in-house manufacturing of recombinant GAD65 at its facility in Umeå, Sweden. Diamyd Medical has no marketed products and generates no product revenue, funding its operations primarily through equity financings, grants, and partnerships. Its activities span clinical development, immunotherapy research, and biologics manufacturing, with operations based in Sweden and trial sites in Europe and the United States.
39GF Score
Get the complete analysis for FRA:DMN
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
